| 摘要 |
A new DNA sequence (I) comprises: (a) a first sequence encoding a natural or mutated sub-unit of a bacterial toxin which causes enzymatic ADP-ribosylating activity; and (b) a second sequence encoding a peptide, resulting in expression of a water-soluble fusion protein (FP) that can be guided to a specific cell receptor, different from the receptor of the native toxin, enabling the intracellular intake of at least this sub-unit to be regulated. Also claimed are: (1) FP, (2) compsns. for increasing immunofunction, e.g. potentiating immune responses, contg. FP in a pharmaceutically compatible diluent or carrier, (3) recombinant expression vectors contg. (I), and (4) transformed bacterial cells contg. one of these vectors. |
